These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 12793013

  • 1. [Development of bladder cancer chemoprevention].
    Dai G, Wang X.
    Wei Sheng Yan Jiu; 2003 Mar; 32(2):159-62. PubMed ID: 12793013
    [Abstract] [Full Text] [Related]

  • 2. Chemoprevention of superficial bladder cancer.
    Kamat AM.
    Expert Rev Anticancer Ther; 2003 Dec; 3(6):799-808. PubMed ID: 14686702
    [Abstract] [Full Text] [Related]

  • 3. Expression of cyclooxygenase-2 in primary superficial bladder cancer tissue may predict risk of its recurrence after complete transurethral resection.
    Okajima E, Uemura H, Ohnishi S, Tanaka M, Ohta M, Tani M, Fujimoto K, Ozono S, Okajima E, Hirao Y.
    Aktuelle Urol; 2003 Jul; 34(4):256-8. PubMed ID: 14566678
    [Abstract] [Full Text] [Related]

  • 4. Potential chemoprevention effect of dietary fucoxanthin on urinary bladder cancer EJ-1 cell line.
    Zhang Z, Zhang P, Hamada M, Takahashi S, Xing G, Liu J, Sugiura N.
    Oncol Rep; 2008 Nov; 20(5):1099-103. PubMed ID: 18949407
    [Abstract] [Full Text] [Related]

  • 5. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer.
    Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, Penson DF, Matin S, Kamat A, Pisters LL, Lin DW, Katz RL, Brenner DE, Hemstreet GP, Wargo M, Bleyer A, Sanders WH, Clifford JL, Parnes HL, Lippman SM.
    Clin Cancer Res; 2008 Jan 01; 14(1):224-9. PubMed ID: 18172274
    [Abstract] [Full Text] [Related]

  • 6. Watchful waiting for low-grade Ta bladder tumours: the idea would have been unacceptable 30 years ago, but nowadays we are highly interested in the results of this study exploring it.
    Oosterlinck W.
    Eur Urol; 2006 Feb 01; 49(2):215-6. PubMed ID: 16426733
    [No Abstract] [Full Text] [Related]

  • 7. Retinoids in the prevention of bladder cancer.
    Nutting CM, Huddart RA.
    Expert Rev Anticancer Ther; 2001 Dec 01; 1(4):541-5. PubMed ID: 12113086
    [Abstract] [Full Text] [Related]

  • 8. Re: Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients.
    Atan A, Basar MM.
    J Urol; 1999 Nov 01; 162(5):1706. PubMed ID: 10524913
    [No Abstract] [Full Text] [Related]

  • 9. Retinoid receptor mRNA expression profiles in human bladder cancer specimens.
    Boorjian S, Scherr DS, Mongan NP, Zhuang Y, Nanus DM, Gudas LJ.
    Int J Oncol; 2005 Apr 01; 26(4):1041-8. PubMed ID: 15754000
    [Abstract] [Full Text] [Related]

  • 10. The use of chemotherapeutic agents in the prophylaxis of papillary bladder tumours.
    Pavone-Macaluso M, Caramia G, Rizzo FP.
    Urol Int; 1971 Apr 01; 26(5):379-87. PubMed ID: 5136749
    [No Abstract] [Full Text] [Related]

  • 11. [Intravesical therapy: Influence on superficial bladder cancer recurrence].
    García Rodríguez J, Fernández Gómez JM, Escaf Barmadah S, González Alvarez RC, Jalón Monzón A, Martínez Gómez FJ, Sánchez Trilla A, Regadera Sejas J.
    Arch Esp Urol; 2007 Apr 01; 60(1):36-43. PubMed ID: 17408170
    [Abstract] [Full Text] [Related]

  • 12. Urinary bladder cancer: mechanisms of development and progression.
    Kroft SH, Oyasu R.
    Lab Invest; 1994 Aug 01; 71(2):158-74. PubMed ID: 8078295
    [No Abstract] [Full Text] [Related]

  • 13. [BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study].
    Jocham D, von Wietersheim J, Pflüger H, Steiner H, Doehn C, Büttner H, Böhle A, Kausch I.
    Aktuelle Urol; 2009 Mar 01; 40(2):91-9. PubMed ID: 19214951
    [Abstract] [Full Text] [Related]

  • 14. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy.
    Yoshida S, Saito K, Koga F, Yokoyama M, Kageyama Y, Masuda H, Kobayashi T, Kawakami S, Kihara K.
    BJU Int; 2008 Apr 01; 101(8):978-81. PubMed ID: 18190628
    [Abstract] [Full Text] [Related]

  • 15. Intravesical chemotherapy--other agents.
    Smith PH, Cruickshank J, Hetherington JW.
    Prog Clin Biol Res; 1984 Apr 01; 162B():173-9. PubMed ID: 6504895
    [No Abstract] [Full Text] [Related]

  • 16. Epigenetic biomarkers in urothelial bladder cancer.
    Kim WJ, Kim YJ.
    Expert Rev Mol Diagn; 2009 Apr 01; 9(3):259-69. PubMed ID: 19379084
    [Abstract] [Full Text] [Related]

  • 17. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
    Ding GQ, Shen ZJ, Lu J, Jin XD, Chen J, Shi SF.
    Zhonghua Wai Ke Za Zhi; 2005 Nov 15; 43(22):1457-60. PubMed ID: 16318813
    [Abstract] [Full Text] [Related]

  • 18. Results with radical cystectomy for treating bladder cancer: a 'reference standard' for high-grade, invasive bladder cancer.
    Stein JP, Skinner DG.
    BJU Int; 2003 Jul 15; 92(1):12-7. PubMed ID: 12823375
    [No Abstract] [Full Text] [Related]

  • 19. Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer.
    Messing E, Kim KM, Sharkey F, Schultz M, Parnes H, Kim D, Saltzstein D, Wilding G.
    J Urol; 2006 Aug 15; 176(2):500-4. PubMed ID: 16813878
    [Abstract] [Full Text] [Related]

  • 20. Should all patients receive an immediate chemotherapeutic drug instillation after resection of papillary bladder tumors?
    Oosterlinck W, Sylvester R, Babjuk M, Kaasinen E, Böhle A, Palou-Redorta J, Rouprêt M, European Association of Urology Guidelines Committee on Non-Muscle-Invasive Bladder Tumors.
    Eur Urol; 2011 Mar 15; 59(3):374-6. PubMed ID: 21168952
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.